However, it is important to acknowledge the limitations of our study, including the need for validation of HCC subtype categories in other cohorts, clarification of the detailed mechanisms underlying XPO1 and ALOX5 in HCC invasion and metastasis, and the necessity of clinical trials to confirm the efficacy of XPO1i and ALOX5i in treating HCC. The gene discussed is ALOX5; the disease is hepatocellular carcinoma.